Abstract A prospective study was conducted during a oneyear period between 2006 and 2007 to describe the epidemiology of Clostridium difficile-associated disease (CDAD) at University Hospital Basel, Switzerland (UHBS) and to determine phenotypic and genotypic features of C. difficile strains isolated at the Microbiology Laboratory UHBS including strains from regional non-university hospitals. We prospectively identified 78 CDAD cases at UHBS with an incidence of 2.65/1,000 hospitalised patients or 2.3/10,000 patient-days. Sixteen patients (20.5%) were infected with clindamycin-resistant strains of PCR-ribotype 027 during an outbreak at the geriatric hospital. Among 124 single-patient isolates, 28 (22.6%) were resistant to moxifloxacin and 34 (27.4%) were resistant to clindamycin, but all remained susceptible to metronidazole and vancomycin. Of 102 toxigenic isolates, 19 (18.7%) had an 18-bp deletion in the tcdC gene, eight (7.8%) a 39-bp deletion, and one (1.0%) a 54-bp deletion. Genes for binary toxin were present in 27 (21.8%). PCR-ribotype 027 was associated with older age (median age 83.5 vs. 65.5 years, p<0.0001) and longer duration of hospitalisation before onset of disease (median 15.5 vs. 9 days, p=0.014) with a trend towards higher crude mortality, more severe disease, and previous use of macrolides compared to ribotype non-027.
Introduction
Clostridium difficile is one of the most important nosocomial pathogens. It is the most frequent cause of antibioticassociated diarrhoea [1, 2] . C. difficile-associated disease (CDAD) has become an increasing clinical problem in the hospital setting as well as in the community [3] . The spectrum of disease is wide-from asymptomatic colonization, mild or self-limiting diarrhoea to life-threatening pseudomembranous colitis [4] . Recently, a new virulent C. difficile strain characterised as toxinotype III, North American pulsed-field type 1, restriction-endonuclease analysis group type BI, and PCR-ribotype 027 has emerged worldwide causing outbreaks in North America and Europe [4, 5] . CDAD due to this hypervirulent strain is associated with increased morbidity and mortality [6] [7] [8] . It has been suggested that increased virulence results from hyperproduction of toxins A and B as a result of deletions in the putative negative regulator gene (tcdC) leading to truncated amino acid residues with insufficient function [9] . More severe disease and a higher case-fatality rate have also been associated with C. difficile strains producing actin-specific ADP-ribosyltransferase (binary toxin) [6, 10] . Other toxinvariant strains such as toxin A-negative/toxin B-positive and toxin A-positive/toxin B-negative strains are also associated with disease or outbreaks [11, 12] .
In this study, we aimed to determine phenotypic and genotypic features of C. difficile strains isolated at the Microbiology Laboratory of the University Hospital Basel, Switzerland during a one-year period between 2006 and 2007. Furthermore, we prospectively identified all CDAD cases including a first cluster of 16 CDAD patients with clindamycin-resistant C. difficile PCR-ribotype 027 at University Hospital Basel and the affiliated geriatric hospital in Basel (UHBS) [13] during the same study period. We analysed clinical and epidemiological patient data as well as the corresponding C. difficile isolates in order to compare strain characteristics with clinical presentation.
Material and methods

Microbiological analyses
All faecal specimens from patients suspected of having CDAD and submitted to the laboratory for C. difficile testing between June 2006 and July 2007 were included in the study. Specimens were sent by UHBS and surrounding hospitals. Samples were tested for toxin A/B using the enzyme-linked immunosorbent assay C.DIFF TOX A/B II (TechLab/Wampole, Blacksburg, VA, USA) according to manufacturer's instructions and simultaneously cultured as previously described [14] . DNA was extracted with LC MagnaPure systems (Roche Diagnostics, Rotkreuz, Switzerland). A single patient isolate was defined as an isolate per patient including repetitive isolates if at least four weeks apart. Genes for toxins A/B and binary toxin were detected by PCR [15] ; the tcdC genotype was determined by sequencing [15, 16] . Ribotyping was performed by the methods of Stubbs et al. [17] . Antibiotic susceptibility to metronidazole, moxifloxacin, clindamycin, and vancomycin was determined by Etest (AB Biodisk, Solna, Sweden) and interpreted in accordance with the Clinical and Laboratory Standards Institute [18] . MICs ≥8 mg/l for moxifloxacin and MICs ≥8 mg/l for clindamycin were regarded as resistant; MICs ≤8 mg/l for metronidazole and MICs ≤2 mg/l for vancomycin were deemed susceptible.
Clinical data and definitions
The UHBS is a 680-bed tertiary care centre with 27,000 admissions and 167,000 outpatients per year. In 2001, the UHBS initiated a surveillance system for C. difficile. Cases are classified as asymptomatic carrier, mild or severe CDAD. For the purpose of this study, additional data from cases were prospectively completed by full-chart review using a standardized case report form over 12 months. Data cleaning was performed by manually reviewing the charts by a board-certified infectious diseases specialist and by checking for outliers in the analyses. The following date were collected: demographic data (age, sex), duration of hospitalisation, hospital ward, symptoms of CDAD (diarrhoea defined as more than three episodes per day), fever, relevant laboratory results (C-reactive protein, white blood cell count, albumin), antibiotic therapy, comorbidity using the Charlson index [19] , McCabe classification [20] , and tcdC putative negative regulator gene, + presence, -absence underlying diseases according to the International Classification of Diseases (ICD, 10th edition). They were matched with the microbiological results obtained from C. difficile patient isolates during the same study period including cases with clindamycin-resistant C. difficile PCR-ribotype 027 from a cluster previously reported [13] . CDAD was defined by the presence of diarrhoea and a positive result for toxin A/B or a patient suffering from diarrhoea, a positive C. difficile stool culture, a clinical diagnosis in the chart, plus a therapy with vancomycin or metronidazole [21, 22] . A complicated clinical course was defined as admission to an intensive care unit, need for surgical intervention, or death. Recurrent CDAD was considered if a positive toxin or stool culture was detected within three months after first diagnosis; reinfection was defined when a new CDAD episode was diagnosed after three months during the same hospitalisation or during a new hospitalisation. A case of CDAD was classified as severe if one of the following complications occurred: paralytic ileus, toxic megacolon, severe dehydration, or severe sepsis. Cases were classified as moderate if at least three or as mild if less than three of the following symptoms were present: fever >38.5°C, severe diarrhoea, abdominal pain, and leukocytosis (>10 9 /l).
Statistical analyses
SPSS statistical software version 14.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Odds ratios (OR) of binary, categorical, or continuous variables were determined by logistic regression (univariate). Statistical significance of dichotomous variables was achieved by using χ 2 , Fisher's exact, or nonparametric tests when appropriate.
Results
Analysis of strains
The phenotypic and genotypic features of 124 singlepatient isolates are given in Table 1 . A total of 98 isolates (79%) were obtained from UHBS and 26 (21%) from surrounding hospitals. Overall, 103 strains (83.1%) were toxigenic (101 toxin A and B positive, two toxin A positive and B negative). PCR-ribotype 027 was detected in 18 isolates. The tcdC gene was not detected in 1/103 (1%) toxigenic isolates (strain was toxin A positive and B negative). Most frequent tcdC genotypes were wild-types, tcdC-sc1, and tcdC-A (Table 1) . Genotypes tcdC-WT1 to WT4 showed no deletions in their sequences and were therefore considered as wild-type (GeneBank accession no. EU075382, EU075378, EU075379, and EU075380). tcdC-A (39-bp deletion), tcdC-B (18-bp deletion), and tcdC-sc1 (18-bp deletion plus single nucleotide deletion at position 117) correspond to genotypes previously described [9, 16] whereas the sequence of tcdC-UHBS2 with a 54-bp deletion is newly recognized (GeneBank accession no. EU075381).
All strains with ribotype 027 were moxifloxacin resistant (MIC >32 mg/l, sensitivity 100%), and the frequency of resistance to moxifloxacin among non-027 strains was 9.4% (specificity 90.6%) ( Table 1) . Among toxigenic strains, MIC 50 and MIC 90 for metronidazole and vancomycin were 0.064 mg/l and 0.25 mg/l, 0.5 mg/l and 1.5 mg/l, respectively, and therefore interpreted as susceptible.
Epidemiological data and patient characteristics
Among the microbiologically analysed single-patient isolates during the study period, 78 fulfilled the case definition of CDAD and complete data from chart review was available. Among these, ten CDAD cases were toxinnegative but suffered from diarrhoea, were C. difficile culture positive, and were treated for CDAD. In eight cases, the strain was not available for further microbiological analysis. Overall, incidence was 2.65 per 1,000 hospitalized patients and 2.3 per 10,000 patient-days. Among all CDAD cases, 61.5% were older than 65 years, 62.8% had a mild clinical course, crude mortality was 9%, frequency of community-onset of CDAD was 2.6%, and recurrence rate was 3.8% ( Table 2 ). The median duration of hospitalisation before onset of diarrhoea was 11.5 days; 91% of patients had documented antibiotic therapy before disease onset and most common underlying disease/diagnosis was rehabilitation, neoplasm, and infectious disease. Only four (5.1%) did not receive a specific treatment, but all of them were toxin-positive. (Table 3) , but repeated toxin testing from C. difficile cultures from specimens that were toxin-negative directly from stool considerably increased sensitivity. In the non-027 group, seven patients underwent chemotherapy compared to zero patients in the 027 group.
Disease severity according to strain and patient characteristics Disease severity of CDAD according to strain and patients' characteristics is summarized in Table 4 . For two patients, the severity of disease was not assessable. The univariate analysis showed that moderate to severe CDAD is statistically significant associated with use of a nasogastric tube and with a shorter hospital stay before onset of diarrhoea (Table 4) . Toxin A/B positivity directly detected from stool (instead of positive only from culture isolate testing) was significantly associated with moderate to severe disease ( p=0.048). We did not observe an association between severity of disease and PCR-ribotype 027, tcdC genotype, as well as presence of binary toxin A/B. There was a trend towards more frequent recurrences and reinfection in the more severe disease group; however, the sample size was too small to infer an association. [23] and from a recent European survey (0.13-7.1/10,000 patient-days) [6] . The incidence of CDAD remained stable at the University Hospital, but increased during an outbreak with C. difficile PCR-ribotype 027 in January 2007 at the affiliated geriatric hospital [13] . The slightly higher incidence compared to the Netherlands may be partly explained by the definitions used. The new guidelines such as those issued by the European Centre for Disease Prevention and Control (ECDC) define CDAD more stringently [4, 24] than what was used in our study. These new guidelines require the detection of toxin that was negative in ten (13%) of our cases, but fulfilled the Centers for Disease Control and Prevention (CDC) surveillance definition [22] . CDAD cases were similar to those of other European countries regarding age, sex, and severity of disease [10, 23] . In contrast to these studies, community-onset CDAD was rare (only 2.6%) in this study and the recurrence rate was lower.
Among all C. difficile strains isolated at the Microbiology Laboratory during the study period, rates of resistance to moxifloxacin and clindamycin were overall rather low, but in the range of a recent European survey [6] . Moxifloxacin resistance was highly associated with the presence of PCRribotype 027; however, these strains were isolated from an outbreak, potentially biasing the strength of this association.
Comparing CDAD due to PCR-ribotype 027 with non 027, ribotype 027 was significantly associated with older age and longer duration of hospital stay before onset of disease. Although a trend was seen towards higher crude mortality, a more severe clinical course, previous use of macrolides, and a longer duration of antibiotic therapy in the 027 patient group, these findings did not reach a statistically significant level, possibly due to small sample size. However, results from previous reports support the observed trends [6, 7] . In contrast to the latter studies, our 027 strains were all clindamycin-resistant. It is noteworthy that previous use of macrolides was more strongly associated with PCR-ribotype 027 than use of quinolones, but both were statistically not significant.
Severe to moderate disease correlated with use of a nasogastric tube and shorter duration of hospitalisation before onset of diarrhoea. Strikingly, the clinical course of CDAD in patients under chemotherapy was mild; these patients were predominantly cared for in a special haematological unit where immediate treatment with metronidazole after onset of any kind of diarrhoea is standard of care. Disease severity was not linked to the presence of tcdC deletions or binary toxin in contrast to previous findings [6, 10] . However, the percentage of binary-toxin positive strains among CDAD cases was quite high (37%) compared to the average among all strains isolated at the laboratory (22%) from patients with and without clinical symptoms. Patients with toxin-positive stool specimens experienced a more severe disease (compared to patients with toxinnegative faeces but with a toxigenic culture result), possibly due to higher stool toxin levels. The disease is mediated by toxins A and B, but toxin levels and bacterial counts in stool are probably affected by many factors and there seems to be no correlation between severity of disease and faecal toxin level [4, 25] . Surprisingly, two strains were toxin A positive but toxin B negative by the PCR method we used. They were isolated from two patients without CDAD diagnosis. This is a rare observation that requires confirmation [11] .
A limitation of our study is the relatively small number of total CDAD cases and the small subgroup of patients infected with ribotype 027 during the 12-month period. However, all consecutive cases were included, clinical data were complete and comprehensive, and isolates were genotypically and phenotypically well characterised. The follow-up period varied but was at least one month, and we cannot rule out that recurrences were treated in the outpatient setting. But seriously ill patients requiring hospitalization are unlikely to go elsewhere since the University Hospital is the only tertiary care hospital in the region.
Based on our study, we propose the introduction of laboratory-based and epidemiological surveillance systems, at least periodically and in populations at high risk. Susceptibility testing of culture isolates for moxifloxacin may serve as a basic screening marker for the epidemic ribotype 027 strains. Incidence and clinical presentation of CDAD cases must be monitored combined with molecular characterisation of strains to detect emergence of new epidemic strains.
